PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
173719-3	1976	When 1 mM L-3,4-dehydroproline was added to the culture medium the [14C]hydroxyproline content was reduced 40% in the cell layer and 70% in the medium.	Carbon-14	68-71	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	10-13
7371936-0	1980	Influence of exogenous L-3,4,-dihydroxyphenylalanine (L-dopa) on the methionine and s-adenosylmethionine concentrations in the brain and other tissues [proceedings].	Levodopa	54-60	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	23-52
7371936-0	1980	Influence of exogenous L-3,4,-dihydroxyphenylalanine (L-dopa) on the methionine and s-adenosylmethionine concentrations in the brain and other tissues [proceedings].	Methionine	69-79	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	23-52
7371936-0	1980	Influence of exogenous L-3,4,-dihydroxyphenylalanine (L-dopa) on the methionine and s-adenosylmethionine concentrations in the brain and other tissues [proceedings].	S-Adenosylmethionine	84-104	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	23-52
591179-0	1977	Synthesis, biological activity, and tritiation of L-3, 4-dehydroproline-containing peptides.	Peptides	83-91	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	50-53
173719-3	1976	When 1 mM L-3,4-dehydroproline was added to the culture medium the [14C]hydroxyproline content was reduced 40% in the cell layer and 70% in the medium.	Hydroxyproline	72-86	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	10-13
173719-5	1976	These findings indicate that L-3,4-dehydroline reduced the hydroxylation of the susceptible prolyl residues in the collagen molecule and the secretion of collagen from the cell.	Peptide oostatic hormone	92-98	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	29-32
173719-6	1976	The reduction in the hydroxyproline content is probably related in part to a reduction in the activity of prolyl hydroxylase; when various mammalian cell cultures were exposed to 0.2 mM L-3,4-dehydroproline, the specific activity of prolyl hydroxylase was reduced markedly, while that of lysyl hydroproline, the specific activity of prolyl hydroxylase was reduced markedly, while that of lysyl hydroxylase was not affected.	Hydroxyproline	21-35	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	186-189
22098598-9	2012	Sagittal Gd-enhanced T1-weighted MR imaging demonstrated an intradural, extramedullary, and uniformly enhancing mass that extended from L-3 to L-4.	Gadolinium	9-11	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	136-139
808981-0	1975	Facile synthesis of L-3-(3,4-dihydroxyphenyl)alanine (L-DOPA) and related compounds.	Levodopa	54-60	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	20-23
803374-0	1975	The incorporation of L-3-glycerolphosphate into lipid and polyglycerolphosphate.	polyglycerolphosphate	58-79	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	21-24
4719312-0	1973	The effect of L-3,4-dihydroxyphenylalanine administration on glucose metabolism in brain.	Glucose	61-68	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	14-17
29749088-1	2018	In this study, poly(mandelate-co-glycolate) (PMG), a modified polyglycolide (PGL), is prepared by ring-opening polymerization (ROP) of L-3-phenyl-1,4-dioxane-2,5-dione (PDD); the cyclic dimer of biobased mandelic acid and glycolic acid.	poly(mandelate-co-glycolate)	15-43	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	135-138
29749088-1	2018	In this study, poly(mandelate-co-glycolate) (PMG), a modified polyglycolide (PGL), is prepared by ring-opening polymerization (ROP) of L-3-phenyl-1,4-dioxane-2,5-dione (PDD); the cyclic dimer of biobased mandelic acid and glycolic acid.	N-PYRIDOXYL-2-METHYL-L-GLUTAMIC ACID-5'-MONOPHOSPHATE	45-48	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	135-138
29749088-1	2018	In this study, poly(mandelate-co-glycolate) (PMG), a modified polyglycolide (PGL), is prepared by ring-opening polymerization (ROP) of L-3-phenyl-1,4-dioxane-2,5-dione (PDD); the cyclic dimer of biobased mandelic acid and glycolic acid.	Polyglycolic Acid	62-75	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	135-138
29749088-1	2018	In this study, poly(mandelate-co-glycolate) (PMG), a modified polyglycolide (PGL), is prepared by ring-opening polymerization (ROP) of L-3-phenyl-1,4-dioxane-2,5-dione (PDD); the cyclic dimer of biobased mandelic acid and glycolic acid.	mandelic acid	204-217	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	135-138
29749088-1	2018	In this study, poly(mandelate-co-glycolate) (PMG), a modified polyglycolide (PGL), is prepared by ring-opening polymerization (ROP) of L-3-phenyl-1,4-dioxane-2,5-dione (PDD); the cyclic dimer of biobased mandelic acid and glycolic acid.	glycolic acid	222-235	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	135-138
28300189-1	2017	Host-guest complexation of cucurbit[8]uril (Q[8]) with two enantiomers, D-3-(2-naphthyl)-alanine (D-NA) and L-3-(2-naphthyl)-alanine (L-NA), has been fully investigated.	cucurbit(8)uril	27-42	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	108-111
27330884-0	2016	Advantages of L-3-[(18)F] fluoro-alpha-methyl tyrosine over 2-[(18)F]-fluoro-2-deoxyglucose in detecting liver metastasis during positron emission tomography scan.	Fluorine	22-24	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	14-17
27330884-0	2016	Advantages of L-3-[(18)F] fluoro-alpha-methyl tyrosine over 2-[(18)F]-fluoro-2-deoxyglucose in detecting liver metastasis during positron emission tomography scan.	fluoro-alpha-methyl tyrosine	26-54	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	14-17
27330884-1	2016	PURPOSE: We aimed to assess the usefulness of positron emission tomography (PET) using the amino acid tracer L-3-[18F] fluoro-alpha-methyl tyrosine (FAMT) in detecting metastatic liver lesions compared with 2-[18F]-fluoro-2-deoxyglucose (FDG).	UNII-BI3A0TJ5AX	149-153	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	109-112
27330884-1	2016	PURPOSE: We aimed to assess the usefulness of positron emission tomography (PET) using the amino acid tracer L-3-[18F] fluoro-alpha-methyl tyrosine (FAMT) in detecting metastatic liver lesions compared with 2-[18F]-fluoro-2-deoxyglucose (FDG).	2-[18f]-fluoro-2-deoxyglucose	207-236	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	109-112
27330884-1	2016	PURPOSE: We aimed to assess the usefulness of positron emission tomography (PET) using the amino acid tracer L-3-[18F] fluoro-alpha-methyl tyrosine (FAMT) in detecting metastatic liver lesions compared with 2-[18F]-fluoro-2-deoxyglucose (FDG).	fluorescein-digalactoside	238-241	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	109-112
25234256-4	2014	In contrast, when the imidazole groups in L(1) are replaced with benzoimidazole groups (L(3)), L(3) also yields the 4:2 complex [(L(3))4-(Zn(2+))2] at a molar ratio of 0.50.	imidazole	22-31	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	95-99
25234256-4	2014	In contrast, when the imidazole groups in L(1) are replaced with benzoimidazole groups (L(3)), L(3) also yields the 4:2 complex [(L(3))4-(Zn(2+))2] at a molar ratio of 0.50.	imidazole	22-31	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	95-99
25234256-4	2014	In contrast, when the imidazole groups in L(1) are replaced with benzoimidazole groups (L(3)), L(3) also yields the 4:2 complex [(L(3))4-(Zn(2+))2] at a molar ratio of 0.50.	benzimidazole	65-79	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	88-92
25234256-4	2014	In contrast, when the imidazole groups in L(1) are replaced with benzoimidazole groups (L(3)), L(3) also yields the 4:2 complex [(L(3))4-(Zn(2+))2] at a molar ratio of 0.50.	benzimidazole	65-79	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	95-99
25234256-4	2014	In contrast, when the imidazole groups in L(1) are replaced with benzoimidazole groups (L(3)), L(3) also yields the 4:2 complex [(L(3))4-(Zn(2+))2] at a molar ratio of 0.50.	benzimidazole	65-79	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	95-99
23799780-5	2013	The ligands 1,3-dppeb (L(3)) and 2,6-dppep (L(4)) give achiral, triple-stranded, dinuclear mesocates with the formula M2(L)3I2 (M = Cu(+) or Au(+)).	1,3-dppeb	12-21	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	23-27
23799780-5	2013	The ligands 1,3-dppeb (L(3)) and 2,6-dppep (L(4)) give achiral, triple-stranded, dinuclear mesocates with the formula M2(L)3I2 (M = Cu(+) or Au(+)).	Copper	132-134	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	23-27
23799780-5	2013	The ligands 1,3-dppeb (L(3)) and 2,6-dppep (L(4)) give achiral, triple-stranded, dinuclear mesocates with the formula M2(L)3I2 (M = Cu(+) or Au(+)).	Gold	141-143	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	23-27
33850196-2	2021	Molecular docking using crystal structures of the ligand binding domains (LBDs) of LXRalpha and beta revealed high docking scores for L3 and D3 hydroxymetabolites, similar to those of the natural ligands, predicting good binding to the receptor.	hydroxymetabolites	144-162	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	134-143
25203415-1	2014	The recombination of CCl3 radicals with CH3, CH3CH2, and CF3CH2 radicals was used to generate CH3CCl3, CH3CH2CCl3, and CF3CH2CCl3 molecules with approximately 87 kcal mol(-1) of vibrational energy in a bath gas at room temperature.	methyl radical	40-43	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	103-113
25203415-1	2014	The recombination of CCl3 radicals with CH3, CH3CH2, and CF3CH2 radicals was used to generate CH3CCl3, CH3CH2CCl3, and CF3CH2CCl3 molecules with approximately 87 kcal mol(-1) of vibrational energy in a bath gas at room temperature.	ch3ch2	45-51	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	103-113
25203415-1	2014	The recombination of CCl3 radicals with CH3, CH3CH2, and CF3CH2 radicals was used to generate CH3CCl3, CH3CH2CCl3, and CF3CH2CCl3 molecules with approximately 87 kcal mol(-1) of vibrational energy in a bath gas at room temperature.	2,2,2-Trifluoroethyl radical	57-63	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	103-113
25203415-5	2014	The assigned threshold energies are 52 +- 2, 50 +- 2, and 52 +- 2 kcal mol(-1) for CH3CCl3, CH3CH2CCl3, and CF3CH2CCl3, respectively, and the CH3 and CF3 groups have only a minor effect on the threshold energies for HCl elimination.	Hydrochloric Acid	216-219	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	92-102
24412974-1	2014	Here we report the first example of a hydrogelator made of a conjugate of nucleobase-saccharide-amino acids by incorporating L-3-(2-naphthyl)-alanine to the conjugate, which illustrates a facile and effective method for generating bioactive and functional hydrogelators from the basic biological building blocks.	nucleobase-saccharide-amino acids	74-107	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	125-128
23281915-1	2013	L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia is a complication of dopaminergic treatment in Parkinson"s disease.	Levodopa	30-36	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-3
21757268-6	2011	The results from in vitro transfection in HEK 293T and A549 cell lines showed that the transfection efficiency of L3/DOPE/DNA lipoplex at an N/P ratio of 6 and lipid/DOPE mole ratio of 1:2 is slightly higher than that of Lipofectamine 2000 , indicating that the title PNA monomer-based cationic lipids have great potential to be efficient non-viral gene vector.	Lipofectamine	221-239	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	114-121
21811711-2	2011	The outstanding UV-Vis absorption properties of the 1-aminoanthraquinone chromophore allowed the efficient visual detection and quantification of copper(II) ions by chelators L(1)-L(3) in buffered aqueous solution.	1-aminoanthraquinone	52-72	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	180-184
21811711-2	2011	The outstanding UV-Vis absorption properties of the 1-aminoanthraquinone chromophore allowed the efficient visual detection and quantification of copper(II) ions by chelators L(1)-L(3) in buffered aqueous solution.	cupric ion	146-156	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	180-184
21811711-5	2011	Detailed potentiometric and spectrophotometric analysis of Cu(2+) complexation by L(2) and L(3), as well as Pb(2+) and Cd(2+) by L(3) was undertaken in order to gain a deeper insight into the pH-dependent speciation and understanding the color changing process.	cupric ion	59-65	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	91-95
21811711-5	2011	Detailed potentiometric and spectrophotometric analysis of Cu(2+) complexation by L(2) and L(3), as well as Pb(2+) and Cd(2+) by L(3) was undertaken in order to gain a deeper insight into the pH-dependent speciation and understanding the color changing process.	Lead	108-110	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	129-133
21928777-1	2011	This report outlines the determination of a reaction mechanism that can be manipulated to develop directed syntheses of gold monolayer-protected clusters (MPCs) prepared by reduction of solutions containing 1,3-bis(diphenylphosphino)propane (L(3)) ligand and Au(PPh(3))Cl.	1,3-bis(diphenylphosphino)propane	207-240	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	242-246
21928777-1	2011	This report outlines the determination of a reaction mechanism that can be manipulated to develop directed syntheses of gold monolayer-protected clusters (MPCs) prepared by reduction of solutions containing 1,3-bis(diphenylphosphino)propane (L(3)) ligand and Au(PPh(3))Cl.	au(pph(3))cl	259-271	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	242-246
21928777-2	2011	Nanocluster synthesis was initiated by reduction of two-coordinate phosphine-ligated [Au(I)LL"](+) complexes (L, L" = PPh(3), L(3)), resulting in free radical complexes.	phosphine	67-76	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	126-130
21063685-0	2011	L-3-n-butyl-phthalide alleviates hydrogen peroxide-induced apoptosis by PKC pathway in human neuroblastoma SK-N-SH cells.	Hydrogen Peroxide	33-50	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-3
21732687-3	2011	An efficient six-step synthesis of L-3-(6-acetylnaphthalen-2-ylamino)-2-aminopropanoic acid (L-Anap), a genetically encodable and polarity-sensitive fluorescent UAA, has been developed.	L-ANAP	93-99	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	35-38
21732687-3	2011	An efficient six-step synthesis of L-3-(6-acetylnaphthalen-2-ylamino)-2-aminopropanoic acid (L-Anap), a genetically encodable and polarity-sensitive fluorescent UAA, has been developed.	6-Carboxymethyluracil	161-164	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	35-38
21063685-3	2011	L-3-n-butyl-phthalide (L-NBP), an anti-cerebral ischemia agent, has been shown a potential in AD treatment.	l-nbp	23-28	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-3
21077627-2	2010	The triureas (L(1), L(2)) show stronger binding of sulfate than tetraureas (L(3), L(4)) in DMSO because of their better conformational complementarity with sulfate, while the tetraureas display better "water tolerance" benefiting from the chelate effect and hydrophobic effect.	Dimethyl Sulfoxide	91-95	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	76-80
20924502-1	2010	7-N,N-Dibutylamino-2-azaphenanthrene (L(3)), 8-N,N-dibutylamino-2-azachrysene (L(4)) and related Ir(i) complexes or alkylated salts show high second-order NLO responses, as determined by the EFISH technique and DFT calculations.	7-n,n-dibutylamino-2-azaphenanthrene	0-36	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	38-42
20924502-1	2010	7-N,N-Dibutylamino-2-azaphenanthrene (L(3)), 8-N,N-dibutylamino-2-azachrysene (L(4)) and related Ir(i) complexes or alkylated salts show high second-order NLO responses, as determined by the EFISH technique and DFT calculations.	8-n,n-dibutylamino-2-azachrysene	45-77	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	38-42
19373924-1	2009	The conformational study of N-acetyl-N"-methylamide of L-3,4-dehydroproline (Ac-Dhp-NHMe, the Dhp dipeptide) is carried out using hybrid density functional methods with the self-consistent reaction field method in the gas phase and in solution (chloroform and water).	N-acetyl-N'-methylamide	28-51	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	55-58
20131803-9	2010	The metal exchange of [LZn(3)] (L = L(1), trans-L(2), cis-L(2), L(3)) with La(3+) efficiently occurred to give [LZn(2)La], but the trans-olefin linker of the [trans-L(2)Zn(2)La] significantly deforms the structure in such a way that one of the salicylaldoxime moieties does not participate in the coordination.	lzn	112-115	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	64-68
20026252-0	2010	Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.	Oxidopamine	206-223	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	24-27
20026252-1	2010	Dyskinesia eventually develops in the majority of Parkinson"s disease patients treated with l-3,4-dihydroxyphenylalanine (l-DOPA).	Levodopa	122-128	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	92-95
20131803-5	2010	The complexation of the ligands H(4)L (L = L(1), trans-L(2), cis-L(2), L(3)) with zinc(II) acetate (3 equiv) yielded the trinuclear complexes [LZn(3)] with a similar trinuclear core bridged by acetato ligands.	Zinc Acetate	82-98	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	71-75
20131803-7	2010	The trinuclear complexes [LZn(3)] (L = L(1), trans-L(2), cis-L(2), L(3)) can recognize alkaline earth metal ions via site-selective metal exchange.	Metals	102-107	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	67-71
20131803-7	2010	The trinuclear complexes [LZn(3)] (L = L(1), trans-L(2), cis-L(2), L(3)) can recognize alkaline earth metal ions via site-selective metal exchange.	Metals	132-137	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	67-71
20131803-9	2010	The metal exchange of [LZn(3)] (L = L(1), trans-L(2), cis-L(2), L(3)) with La(3+) efficiently occurred to give [LZn(2)La], but the trans-olefin linker of the [trans-L(2)Zn(2)La] significantly deforms the structure in such a way that one of the salicylaldoxime moieties does not participate in the coordination.	Metals	4-9	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	64-68
20131803-9	2010	The metal exchange of [LZn(3)] (L = L(1), trans-L(2), cis-L(2), L(3)) with La(3+) efficiently occurred to give [LZn(2)La], but the trans-olefin linker of the [trans-L(2)Zn(2)La] significantly deforms the structure in such a way that one of the salicylaldoxime moieties does not participate in the coordination.	lzn	23-26	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	64-68
19373924-1	2009	The conformational study of N-acetyl-N"-methylamide of L-3,4-dehydroproline (Ac-Dhp-NHMe, the Dhp dipeptide) is carried out using hybrid density functional methods with the self-consistent reaction field method in the gas phase and in solution (chloroform and water).	Dipeptides	98-107	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	55-58
19373924-1	2009	The conformational study of N-acetyl-N"-methylamide of L-3,4-dehydroproline (Ac-Dhp-NHMe, the Dhp dipeptide) is carried out using hybrid density functional methods with the self-consistent reaction field method in the gas phase and in solution (chloroform and water).	Chloroform	245-255	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	55-58
19373924-1	2009	The conformational study of N-acetyl-N"-methylamide of L-3,4-dehydroproline (Ac-Dhp-NHMe, the Dhp dipeptide) is carried out using hybrid density functional methods with the self-consistent reaction field method in the gas phase and in solution (chloroform and water).	Water	260-265	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	55-58
17927169-1	2007	Magnesium and zinc complexes of the monoanionic ligands N,N"-bis(2,6-di-isopropylphenyl)triazenide, L1, N,N"-bis(2,6-di-isopropylphenyl)acetamidinate, L2, and N,N"-bis(2,6-di-isopropylphenyl)tert-butylamidinate, L3, have been synthesized, but only L3 possesses sufficient steric bulk to prevent bis-chelation.	Magnesium	0-9	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	212-214
18308560-3	2007	These symptoms are greatly improved by pharmacological DA replacement with L-3,4-dihydroxy-phenylalanine (L-DOPA), which however causes excessive involuntary movements in a majority of patients.	Levodopa	106-112	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	75-78
19291720-2	2009	N-salicylidene-3-aminopyridine (L(3)) is a versatile thermo- and photochromic molecule.	n-salicylidene-3-aminopyridine	0-30	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	32-36
19291720-6	2009	L(3) was also used as a ligand in new thermochromic coordination complexes [M(CH(3)OH)(2)(L(3))(2)(NCX)(2)], in which M(II) = Fe, Co, Ni, Cu or Mn and X = S or Se (1-6), which allowed the fine-tuning of the electron density in the photochromic moiety.	Iron	126-128	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-4
19291720-6	2009	L(3) was also used as a ligand in new thermochromic coordination complexes [M(CH(3)OH)(2)(L(3))(2)(NCX)(2)], in which M(II) = Fe, Co, Ni, Cu or Mn and X = S or Se (1-6), which allowed the fine-tuning of the electron density in the photochromic moiety.	Cobalt	130-132	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-4
19291720-6	2009	L(3) was also used as a ligand in new thermochromic coordination complexes [M(CH(3)OH)(2)(L(3))(2)(NCX)(2)], in which M(II) = Fe, Co, Ni, Cu or Mn and X = S or Se (1-6), which allowed the fine-tuning of the electron density in the photochromic moiety.	Copper	138-140	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-4
19291720-6	2009	L(3) was also used as a ligand in new thermochromic coordination complexes [M(CH(3)OH)(2)(L(3))(2)(NCX)(2)], in which M(II) = Fe, Co, Ni, Cu or Mn and X = S or Se (1-6), which allowed the fine-tuning of the electron density in the photochromic moiety.	Sulfur	155-156	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-4
19291720-6	2009	L(3) was also used as a ligand in new thermochromic coordination complexes [M(CH(3)OH)(2)(L(3))(2)(NCX)(2)], in which M(II) = Fe, Co, Ni, Cu or Mn and X = S or Se (1-6), which allowed the fine-tuning of the electron density in the photochromic moiety.	Selenium	160-162	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-4
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tert-butylamidinate	17-36	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	122-124
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tert-butylamidinate	17-36	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	122-124
17927169-1	2007	Magnesium and zinc complexes of the monoanionic ligands N,N"-bis(2,6-di-isopropylphenyl)triazenide, L1, N,N"-bis(2,6-di-isopropylphenyl)acetamidinate, L2, and N,N"-bis(2,6-di-isopropylphenyl)tert-butylamidinate, L3, have been synthesized, but only L3 possesses sufficient steric bulk to prevent bis-chelation.	Magnesium	0-9	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	248-250
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tert-butylamidinate	17-36	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	122-124
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tert-butylamidinate	17-36	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	103-105
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tetrahydrofuran	111-114	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	103-105
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tetrahydrofuran	111-114	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	122-124
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tert-butylamidinate	17-36	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	122-124
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tetrahydrofuran	111-114	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	122-124
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tetrahydrofuran	111-114	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	122-124
17325775-5	2007	In contrast, ligands L(2) and L(3) (with o- and m-phenylene spacers, respectively) generally form dinuclear Ln(2)L(2) Ln(III) complexes in which the two ligands may be arranged in a helical or non-helical architecture about the two metal ions.	Phenylephrine	50-59	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	30-34
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tetrahydrofuran	111-114	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	122-124
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	Ether	174-178	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	103-105
17927169-5	2007	By contrast, the tert-butylamidinate ligand was found to exclusively promote mono-chelation, allowing (L3)ZnCl(THF), 7, [(L3)Zn(micro-Cl)]2, 8, (L3)ZnN(SiMe3)2, 9, (L3)MgiPr(Et2O), 10, and (L3)MgiPr(THF), 11, to be isolated.	tetrahydrofuran	199-202	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	103-105
17927169-6	2007	X-ray crystallographic analyses of 1, 2, 3, 4, 5, 6, 8, and 10 indicate that the capacity of L3 to resist bis-chelation is due to greater occupation of the metal coordination sphere by the N-aryl substituents.	Metals	156-161	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	93-95
17719088-4	2007	Competitive binding studies using fluorescent dyes Hoechst 33258 (a minor groove binder), ethidium bromide (an intercalator) and a major groove binding cation (cobalt (III) hexammine) which induces the B-->Z transition have been employed to determine the binding geometries of the enantiomers of two methylated helicates (L(3) and L(5)) to DNA and compare with the data obtained previously for the unmethylated analogue (L(1)).	cobalt (iii) hexammine	160-182	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	325-329
17325775-5	2007	In contrast, ligands L(2) and L(3) (with o- and m-phenylene spacers, respectively) generally form dinuclear Ln(2)L(2) Ln(III) complexes in which the two ligands may be arranged in a helical or non-helical architecture about the two metal ions.	Metals	232-237	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	30-34
16094474-4	2005	Reaction of L-2 and of [Re(D-ser)(2)(CO)(3)](D-2) with 7-MeG yields complexes [Re(L-ser)(7-MeG)(CO)(3)](L-3) and [Re(D-ser)(7-MeG)(CO)(3)](D-3) respectively.	D-serine	27-32	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	104-107
17424980-0	2007	Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET.	fmt	77-80	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	38-41
17424980-1	2007	OBJECTIVES: To compare L-3-[18F]-fluoro-a-methyltyrosine (FMT)-positron emission tomography (PET) and 2-[18F]-fluoro-2-deoxy-D-glucose (FDG)-PET in the differential diagnosis of maxillofacial tumors.	fmt	58-61	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	23-26
16094474-4	2005	Reaction of L-2 and of [Re(D-ser)(2)(CO)(3)](D-2) with 7-MeG yields complexes [Re(L-ser)(7-MeG)(CO)(3)](L-3) and [Re(D-ser)(7-MeG)(CO)(3)](D-3) respectively.	D-serine	117-122	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	104-107
16094474-4	2005	Reaction of L-2 and of [Re(D-ser)(2)(CO)(3)](D-2) with 7-MeG yields complexes [Re(L-ser)(7-MeG)(CO)(3)](L-3) and [Re(D-ser)(7-MeG)(CO)(3)](D-3) respectively.	co)(3)	37-43	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	104-107
16094474-4	2005	Reaction of L-2 and of [Re(D-ser)(2)(CO)(3)](D-2) with 7-MeG yields complexes [Re(L-ser)(7-MeG)(CO)(3)](L-3) and [Re(D-ser)(7-MeG)(CO)(3)](D-3) respectively.	Serine	82-87	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	104-107
12003573-5	2002	The utility of this strategy is demonstrated by its application to the syntheses of protected derivatives of D- and L-3-amino-3-deoxyxylose, L-3-amino-3-deoxyarabinose, and a late-stage intermediate in a potential route to N-acetylneuraminic acid.	N-Acetylneuraminic Acid	223-246	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	116-119
15673733-1	2005	beta-L-3"-Fluoro-2",3"-didehydro-2",3"-dideoxycytidine (L-3"-Fd4C) is a potent and selective antiretroviral nucleoside with activity against lamivudine-resistant human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV) in vitro.	Nucleosides	108-118	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	5-8
15673733-1	2005	beta-L-3"-Fluoro-2",3"-didehydro-2",3"-dideoxycytidine (L-3"-Fd4C) is a potent and selective antiretroviral nucleoside with activity against lamivudine-resistant human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV) in vitro.	Nucleosides	108-118	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	56-59
15673733-1	2005	beta-L-3"-Fluoro-2",3"-didehydro-2",3"-dideoxycytidine (L-3"-Fd4C) is a potent and selective antiretroviral nucleoside with activity against lamivudine-resistant human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV) in vitro.	Lamivudine	141-151	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	5-8
15673733-1	2005	beta-L-3"-Fluoro-2",3"-didehydro-2",3"-dideoxycytidine (L-3"-Fd4C) is a potent and selective antiretroviral nucleoside with activity against lamivudine-resistant human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV) in vitro.	Lamivudine	141-151	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	56-59
15673733-8	2005	The bioavailability of L-3"-Fd4C administered with sodium bicarbonate was not significantly different from the bioavailability when the oral dose was administered in the absence of buffer (P = 0.49), suggesting that further development of this compound may warrant other approaches, such as development of a prodrug to improve its oral absorption.	Sodium Bicarbonate	51-69	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	23-26
12842104-0	2003	Identification of L-3-hydroxybutyrate as an original ketone body in rat serum by column-switching high-performance liquid chromatography and fluorescence derivatization.	Ketones	53-59	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	18-21
12842104-1	2003	L-3-Hydroxybutyrate (L-3HB), the enantiomer of D-3-hydroxybutyrate (D-3HB), has traditionally been regarded the "unnatural" ketone body in mammals, although there is suspicion that it is a more-favorable energy fuel for mammalian tissues than D-3HB.	l-3hb	21-26	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-3
12842104-1	2003	L-3-Hydroxybutyrate (L-3HB), the enantiomer of D-3-hydroxybutyrate (D-3HB), has traditionally been regarded the "unnatural" ketone body in mammals, although there is suspicion that it is a more-favorable energy fuel for mammalian tissues than D-3HB.	(R)-3-hydroxybutyrate	47-66	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-3
12842104-1	2003	L-3-Hydroxybutyrate (L-3HB), the enantiomer of D-3-hydroxybutyrate (D-3HB), has traditionally been regarded the "unnatural" ketone body in mammals, although there is suspicion that it is a more-favorable energy fuel for mammalian tissues than D-3HB.	d-3hb	68-73	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-3
12842104-1	2003	L-3-Hydroxybutyrate (L-3HB), the enantiomer of D-3-hydroxybutyrate (D-3HB), has traditionally been regarded the "unnatural" ketone body in mammals, although there is suspicion that it is a more-favorable energy fuel for mammalian tissues than D-3HB.	Ketones	124-130	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-3
12842104-1	2003	L-3-Hydroxybutyrate (L-3HB), the enantiomer of D-3-hydroxybutyrate (D-3HB), has traditionally been regarded the "unnatural" ketone body in mammals, although there is suspicion that it is a more-favorable energy fuel for mammalian tissues than D-3HB.	d-3hb	243-248	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-3
12639118-3	2003	Addition of 30% aqueous H(2)O(2) to the methanol solution of the Mn(II) complex of L(3) ([Mn(II)L(3)(CH(3)CN)(H(2)O)](ClO(4))(2) (3)) showed a very sluggish change gradually precipitating an insoluble black gummy solid, but no dioxo-bridged manganese complex is produced.	Hydrogen Peroxide	24-32	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	83-87
12639118-3	2003	Addition of 30% aqueous H(2)O(2) to the methanol solution of the Mn(II) complex of L(3) ([Mn(II)L(3)(CH(3)CN)(H(2)O)](ClO(4))(2) (3)) showed a very sluggish change gradually precipitating an insoluble black gummy solid, but no dioxo-bridged manganese complex is produced.	Hydrogen Peroxide	24-32	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	96-100
12639118-3	2003	Addition of 30% aqueous H(2)O(2) to the methanol solution of the Mn(II) complex of L(3) ([Mn(II)L(3)(CH(3)CN)(H(2)O)](ClO(4))(2) (3)) showed a very sluggish change gradually precipitating an insoluble black gummy solid, but no dioxo-bridged manganese complex is produced.	Methanol	40-48	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	83-87
12639118-3	2003	Addition of 30% aqueous H(2)O(2) to the methanol solution of the Mn(II) complex of L(3) ([Mn(II)L(3)(CH(3)CN)(H(2)O)](ClO(4))(2) (3)) showed a very sluggish change gradually precipitating an insoluble black gummy solid, but no dioxo-bridged manganese complex is produced.	Manganese(2+)	65-71	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	83-87
12639118-3	2003	Addition of 30% aqueous H(2)O(2) to the methanol solution of the Mn(II) complex of L(3) ([Mn(II)L(3)(CH(3)CN)(H(2)O)](ClO(4))(2) (3)) showed a very sluggish change gradually precipitating an insoluble black gummy solid, but no dioxo-bridged manganese complex is produced.	Manganese(2+)	65-71	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	96-100
12639118-3	2003	Addition of 30% aqueous H(2)O(2) to the methanol solution of the Mn(II) complex of L(3) ([Mn(II)L(3)(CH(3)CN)(H(2)O)](ClO(4))(2) (3)) showed a very sluggish change gradually precipitating an insoluble black gummy solid, but no dioxo-bridged manganese complex is produced.	Water	110-116	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	83-87
12639118-3	2003	Addition of 30% aqueous H(2)O(2) to the methanol solution of the Mn(II) complex of L(3) ([Mn(II)L(3)(CH(3)CN)(H(2)O)](ClO(4))(2) (3)) showed a very sluggish change gradually precipitating an insoluble black gummy solid, but no dioxo-bridged manganese complex is produced.	Water	110-116	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	96-100
12639118-3	2003	Addition of 30% aqueous H(2)O(2) to the methanol solution of the Mn(II) complex of L(3) ([Mn(II)L(3)(CH(3)CN)(H(2)O)](ClO(4))(2) (3)) showed a very sluggish change gradually precipitating an insoluble black gummy solid, but no dioxo-bridged manganese complex is produced.	clo	118-121	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	83-87
12639118-3	2003	Addition of 30% aqueous H(2)O(2) to the methanol solution of the Mn(II) complex of L(3) ([Mn(II)L(3)(CH(3)CN)(H(2)O)](ClO(4))(2) (3)) showed a very sluggish change gradually precipitating an insoluble black gummy solid, but no dioxo-bridged manganese complex is produced.	Manganese	241-250	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	83-87
12639118-9	2003	The Mn(II) complex of L(3) shows a quasi reversible peak at an anodic potential of E(p,a) of 1.96 V (vs Ag/AgCl) assigned to the oxidation Mn(II) to Mn(III) complex.	Manganese(2+)	4-10	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	22-26
12639118-9	2003	The Mn(II) complex of L(3) shows a quasi reversible peak at an anodic potential of E(p,a) of 1.96 V (vs Ag/AgCl) assigned to the oxidation Mn(II) to Mn(III) complex.	silver chloride	107-111	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	22-26
12639118-9	2003	The Mn(II) complex of L(3) shows a quasi reversible peak at an anodic potential of E(p,a) of 1.96 V (vs Ag/AgCl) assigned to the oxidation Mn(II) to Mn(III) complex.	Manganese(2+)	139-145	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	22-26
12639118-9	2003	The Mn(II) complex of L(3) shows a quasi reversible peak at an anodic potential of E(p,a) of 1.96 V (vs Ag/AgCl) assigned to the oxidation Mn(II) to Mn(III) complex.	manganese(III) acetate dihydrate	149-156	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	22-26
12003573-5	2002	The utility of this strategy is demonstrated by its application to the syntheses of protected derivatives of D- and L-3-amino-3-deoxyxylose, L-3-amino-3-deoxyarabinose, and a late-stage intermediate in a potential route to N-acetylneuraminic acid.	N-Acetylneuraminic Acid	223-246	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	141-144
11886804-0	2002	Certification of the critical importance of L-3-(2-naphthyl)alanine at position 3 of a specific CXCR4 inhibitor, T140, leads to an exploratory performance of its downsizing study.	T140 peptide	113-117	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	44-47
11886804-2	2002	Here, the importance of an L-3-(2-naphthyl)alanine (Nal) residue at position 3 in T140 for high anti-HIV activity and inhibitory activity against Ca(2+) mobilization induced by stromal cell-derived factor (SDF)-1alpha-stimulation through CXCR4 has initially been shown by the synthesis and biological evaluation of several analogues, where Nal(3) is substituted by diverse aromatic amino acids.	acetylleucine	52-55	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	27-30
11886804-2	2002	Here, the importance of an L-3-(2-naphthyl)alanine (Nal) residue at position 3 in T140 for high anti-HIV activity and inhibitory activity against Ca(2+) mobilization induced by stromal cell-derived factor (SDF)-1alpha-stimulation through CXCR4 has initially been shown by the synthesis and biological evaluation of several analogues, where Nal(3) is substituted by diverse aromatic amino acids.	Amino Acids, Aromatic	373-393	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	27-30
11315593-2	2001	This retrospective analysis was conducted to determine whether scintigraphic features of malignancy are also found on single-photon emission tomography (SPET) using L-3-[123I]iodo-alpha-methyl tyrosine (IMT) as a tracer.	3-iodo-alpha-methyltyrosine	203-206	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	165-168
11761100-1	2001	L-3-[123I]iodo-alpha-methyl tyrosine (IMT) is an artificial amino acid suitable for SPECT imaging of various tumours.	3-iodo-alpha-methyltyrosine	38-41	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	0-3
8913337-0	1996	Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	83-127	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	171-174
11764407-1	2001	An efficient synthesis of L-3-(1"-pyrenyl)alanine (Pya), a highly fluorescent amino acid, is described.	1-pyrenylalanine	51-54	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	26-29
11079485-2	2000	Our aim was to evaluate the tyrosine analog L-3-[123I]iodo-alpha-methyltyrosine (IMT) in the detection and the determination of biochemical activity of these tumors in comparison with 111In-labeled [diethylenetriaminepentaacetic acid (DTPA)-D-Phe1]-octreotide (111In-octreotide) scintigraphy.	Tyrosine	28-36	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	44-47
11079485-2	2000	Our aim was to evaluate the tyrosine analog L-3-[123I]iodo-alpha-methyltyrosine (IMT) in the detection and the determination of biochemical activity of these tumors in comparison with 111In-labeled [diethylenetriaminepentaacetic acid (DTPA)-D-Phe1]-octreotide (111In-octreotide) scintigraphy.	3-iodo-alpha-methyltyrosine	81-84	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	44-47
11079485-2	2000	Our aim was to evaluate the tyrosine analog L-3-[123I]iodo-alpha-methyltyrosine (IMT) in the detection and the determination of biochemical activity of these tumors in comparison with 111In-labeled [diethylenetriaminepentaacetic acid (DTPA)-D-Phe1]-octreotide (111In-octreotide) scintigraphy.	Pentetic Acid	235-240	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	44-47
11079485-2	2000	Our aim was to evaluate the tyrosine analog L-3-[123I]iodo-alpha-methyltyrosine (IMT) in the detection and the determination of biochemical activity of these tumors in comparison with 111In-labeled [diethylenetriaminepentaacetic acid (DTPA)-D-Phe1]-octreotide (111In-octreotide) scintigraphy.	d-phe1]-octreotide	241-259	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	44-47
11079485-2	2000	Our aim was to evaluate the tyrosine analog L-3-[123I]iodo-alpha-methyltyrosine (IMT) in the detection and the determination of biochemical activity of these tumors in comparison with 111In-labeled [diethylenetriaminepentaacetic acid (DTPA)-D-Phe1]-octreotide (111In-octreotide) scintigraphy.	indium-111-octreotide	261-277	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	44-47
10079942-1	1998	To increase the solubility of L-3,4-dihydroxyphenylalanine (DOPA) and dopamine (DA) incorporated in liposomes, it was suggested to convert them into ammonium and 1-adamantylammonium borate complexes.	Levodopa	60-64	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	30-33
10079942-1	1998	To increase the solubility of L-3,4-dihydroxyphenylalanine (DOPA) and dopamine (DA) incorporated in liposomes, it was suggested to convert them into ammonium and 1-adamantylammonium borate complexes.	Ammonium Compounds	149-157	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	30-33
10079942-1	1998	To increase the solubility of L-3,4-dihydroxyphenylalanine (DOPA) and dopamine (DA) incorporated in liposomes, it was suggested to convert them into ammonium and 1-adamantylammonium borate complexes.	1-adamantylammonium borate	162-188	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	30-33
9776279-1	1998	UNLABELLED: L-3-[123I]-Iodo-alpha-methyl-tyrosine (IMT) is a modified amino acid.	3-iodo-alpha-methyltyrosine	51-54	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	12-15
11233558-1	2001	The radiolabelled amino acid analogue L-3-[125I]iodo-alpha-methyl-tyrosine (IMT) is under evaluation in brain tumours, where it reflects amino acid transport activity, but is also taken up in many other tumour types.	4-amino-1-methylimidazole-2-carboxylic acid	76-79	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	38-41
10890170-0	2000	Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa.	Levodopa	98-104	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	13-20
10890170-1	2000	The synthesis and in vitro chemical and enzymatic stability of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine (9) as L-Dopa prodrug are described.	Levodopa	131-137	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	63-70
8913337-1	1996	The effect of L-3,4-dihydroxyphenylalanine (L-DOPA) on dopamine receptor gene expression in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys was investigated using in situ hybridization histochemistry with measures of changes in relative absorbance.	Levodopa	44-50	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	14-17
8913337-1	1996	The effect of L-3,4-dihydroxyphenylalanine (L-DOPA) on dopamine receptor gene expression in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys was investigated using in situ hybridization histochemistry with measures of changes in relative absorbance.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	105-149	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	14-17
8897095-3	1996	The optically active starting material was the previously reported cis-3-hydroxyprolinol derivative L-3.	cis-3-hydroxyprolinol	67-88	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	100-103
1939384-1	1991	Characterization of peripheral and cerebral L-3,4-dihydroxy-6-[18F]fluorophenylalanine (FDOPA) metabolism in humans and monkeys has shown FDOPA to be an analogue of L-DOPA for the study of the dopaminergic system with positron emission tomography (PET).	fluorodopa F 18	138-143	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	44-47
1939384-1	1991	Characterization of peripheral and cerebral L-3,4-dihydroxy-6-[18F]fluorophenylalanine (FDOPA) metabolism in humans and monkeys has shown FDOPA to be an analogue of L-DOPA for the study of the dopaminergic system with positron emission tomography (PET).	Levodopa	165-171	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	44-47
1939384-2	1991	In human studies with carbidopa pretreatment, L-3,4-dihydroxy-6-[18F]fluoro-3-O-methylphenylalanine (3-OMFD) was the only FDOPA metabolite detected in plasma.	Carbidopa	22-31	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	46-49
1939384-2	1991	In human studies with carbidopa pretreatment, L-3,4-dihydroxy-6-[18F]fluoro-3-O-methylphenylalanine (3-OMFD) was the only FDOPA metabolite detected in plasma.	3-O-methyl-6-fluoro-dopa	101-107	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	46-49
1939384-2	1991	In human studies with carbidopa pretreatment, L-3,4-dihydroxy-6-[18F]fluoro-3-O-methylphenylalanine (3-OMFD) was the only FDOPA metabolite detected in plasma.	fluorodopa F 18	122-127	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	46-49
1939385-1	1991	Kinetics of L-3,4-dihydroxy-6-[18F]fluorophenylalanine (FDOPA) in striatum and cerebellum were measured in 10 normal human subjects with positron emission tomography (PET) from 0 to 120 min after an intravenous bolus injection of the tracer.	fluorodopa F 18	56-61	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	12-15
2783455-2	1989	This study was undertaken to evaluate the potential of L-3-[123I]-iodo-alpha-methyl tyrosine (123IMT) for metabolic imaging of brain tumors.	123imt	94-100	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	55-58
2045937-0	1991	Brain and brain tumor uptake of L-3-[123I]iodo-alpha-methyl tyrosine: competition with natural L-amino acids.	Amino Acids	95-108	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	32-35
2037651-0	1991	High-performance liquid chromatographic determination of L-3-(3,4-dihydroxyphenyl)-2-methylalanine (alpha-methyldopa) in human urine and plasma.	Methyldopa	100-116	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	57-60
2037651-1	1991	A procedure is described for the determination of alpha-methyldopa (MD) [L-3-(3,4-dihydroxyphenyl)-2-methylalanine], its metabolite and catecholamines in the urine and plasma of patients undergoing MD therapy, by high-performance liquid chromatography with dual working electrode coulometric detection.	Methyldopa	50-66	immunoglobulin kappa variable 2-14 (pseudogene)	Homo sapiens	73-76